MedTrace Logo

Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

NCT06613984 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 660

Last updated 2026-01-14

No results posted yet for this study

Summary

This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.

Conditions

  • COVID-19 Vaccination

Interventions

BIOLOGICAL

Bretovameran

Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-11
Primary Completion
2026-12-30
Completion
2026-12-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613984 on ClinicalTrials.gov